

09-09-04

JFW

Express Mail No.: EV475140988US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan *et al.*

Confirmation No.: 3565

Application No.: 10/657,006

Group Art Unit: 1614

Filed: September 5, 2003

Examiner: To Be Assigned

For: METHODS OF PREVENTING OR
TREATING T CELL
MALIGNANCIES BY
ADMINISTERING CD2
ANTAGONISTS

Attorney Docket No.: 10271-116-999

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01 to A150, B01 to B70, and C01 to C226** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **A01 to A03, B01 to B70, and C01 to C226** are submitted herewith.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.


Respectfully submitted,

Date September 8, 2004


Margaret B. Brivanlou 40,922
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
10271-116-999

APPLICATION NO
10/657.006

APPLICANT
Dingivan et al.

FILING DATE
September 5, 2003

GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	60/410,385	9/12/02	Dingivan			9/12/02
	A02	60/409,024	9/5/02	Dingivan			9/5/02
	A03	10/091,268	3/4/02	Dingivan			3/4/02
	A04	US 2003/0044406	3/6/03	Dingivan			
	A05	6,458,935	10/1/02	Burns et al.			
	A06	6,451,812	9/17/02	End et al.			
	A07	6,440,974	8/27/02	Doll et al.			
	A08	6,436,960	8/20/02	Shin et al.			
	A09	6,432,959	8/13/02	Cooper et al.			
	A10	6,420,387	7/16/02	Venet et al.			
	A11	6,414,145	7/2/02	Boyle et al.			
	A12	6,410,541	6/25/02	Remiszewski et al.			
	A13	6,410,539	6/25/02	Arnould			
	A14	6,407,213	6/18/02	Carter et al.			
	A15	6,403,581	6/11/02	Ayral-Kaloustian et al.			
	A16	6,399,633	6/4/02	Dumont et al.			
	A17	6,399,615	6/4/02	Guzi et al.			
	A18	6,387,905	5/14/02	Njoroge et al.			
	A19	6,383,790	5/7/02	Shokat			
	A20	6,372,747	4/16/02	Taveras et al.			
	A21	6,369,034	4/9/02	Doherty et al.			
	A22	6,362,188	3/26/02	Guzi et al.			
	A23	6,342,765	1/29/02	Arnould			
	A24	6,342,487	1/29/02	Riou et al.			
	A25	6,340,459	1/22/02	Yellin et al.			
	A26	6,335,156	1/1/02	Hermeking et al.			
	A27	6,331,415	12/18/01	Cabilly et al.			
	A28	6,300,501	10/9/01	Dobrusin, et al.			
	A29	6,277,832	8/21/01	Sugiyama et al.			
	A30	6,277,375	8/21/01	Ward			
	A31	6,271,242	8/7/01	Barbacid			
	A32	6,268,363	7/31/01	Lee et al.			
	A33	6,265,422	7/24/01	Bikker et al.			
	A34	6,248,756	6/19/01	Anthony et al.			
	A35	6,245,759	6/12/01	Bilodeau et al.			
	A36	6,242,196	6/5/01	Spiegelman et al.			

A37	6,239,140	5/29/01	Cooper et al.			
A38	6,232,338	5/15/01	Davies et al.			
A39	6,228,865	5/8/01	Doll et al.			
A40	6,228,856	5/8/01	Njoroge et al.			
A41	6,225,322	5/1/01	Cooper et al.			
A42	6,218,410	4/17/01	Uehata et al.			
A43	6,218,406	4/17/01	Bourzat et al.			
A44	6,218,372	4/17/01	Nabel et al.			
A45	6,211,193	4/3/01	Remiszewski et al.			
A46	6,187,786	2/13/01	Venet et al.			
A47	6,169,096	1/2/01	Venet et al.			
A48	6,162,432	12/19/00	Wallner et al.			
A49	6,159,984	12/12/00	Guzi et al.			
A50	6,153,628	11/28/00	Jin et al.			
A51	6,143,766	11/7/00	Kaltenbronn et al.			
A52	6,133,303	10/17/00	Bikker et al.			
A53	6,127,366	10/3/00	Kim et al.			
A54	6,124,465	9/26/00	Bourzat et al.			
A55	6,124,295	9/26/00	Taveras et al.			
A56	6,103,723	8/15/00	Bergman et al.			
A57	6,093,737	7/25/00	Anthony et al.			
A58	6,090,948	7/18/00	Dinsmore et al.			
A59	6,080,870	6/27/00	Anthony et al.			
A60	6,077,853	6/20/00	Graham et al.			
A61	6,071,935	6/6/00	Lyssikatos			
A62	6,066,738	5/23/00	Dinsmore, et al.			
A63	6,063,930	5/16/00	Dinsmore et al.			
A64	6,057,300	5/2/00	Nabel et al.			
A65	6,054,466	4/25/00	Ciccarone et al.			
A66	6,051,582	4/18/00	Taveras			
A67	6,051,574	4/18/00	Anthony			
A68	6,040,305	3/21/00	Taveras et al.			
A69	6,037,454	3/14/00	Jardieu et al.			
A70	6,034,053	3/7/00	Uckun et al.			
A71	6,005,079	12/21/99	Casterman et al.			
A72	5,998,596	12/7/99	Bergan et al.			
A73	5,989,463	11/23/99	Tracy et al.			
A74	5,985,877	11/16/99	Dionne et al.			
A75	5,969,108	10/19/99	McCafferty et al.			
A76	5,962,427	10/5/99	Goldstein et al.			
A77	5,958,769	9/28/99	Roberts et al.			
A78	5,951,983	9/14/99	Bazin et al.			
A79	5,939,598	8/17/99	Kucherlapati et al.			
A80	5,928,643	7/27/99	Wallner et al.			
A81	5,925,376	7/20/99	Heng			

	A82	5,922.844	7/13/99	Hawkins et al.			
	A83	5,916.597	6/29/99	Lee et al.			
	A84	5,914.111	6/22/99	Wallner et al.			
	A85	5,912.015	6/15/99	Bernstein et al.			
	A86	5,911.995	6/15/99	Uckun			
	A87	5,908.626	6/1/99	Chang et al.			
	A88	5,885.834	3/23/99	Epstein			
	A89	5,872.223	2/16/99	Uckun			
	A90	5,863.904	1/26/99	Nabel et al.			
	A91	5,844.095	12/1/98	Linsley et al.			
	A92	5,840.745	11/24/98	Buzzetti et al.			
	A93	5,821.047	10/13/98	Garrard et al.			
	A94	5,817.311	10/6/98	Bazin et al.			
	A95	5,814.318	9/29/98	Lonberg et al.			
	A96	5,807.715	9/15/98	Morrison et al.			
	A97	5,783.181	7/21/98	Browne et al.			
	A98	5,780.225	7/14/98	Wigler et al.			
	A99	5,766.886	6/16/98	Studnicka et al.			
	A100	5,750.753	5/12/98	Kimae et al.			
	A101	5,734.033	3/31/98	Reed			
	A102	5,733.743	3/31/98	Johnson et al.			
	A103	5,730.979	3/24/98	Bazin et al.			
	A104	5,728.868	3/17/98	Springer et al.			
	A105	5,728.677	3/17/98	Wallner et al.			
	A106	5,723.125	3/3/98	Chang et al.			
	A107	5,698.426	12/16/97	Huse			
	A108	5,679.377	10/21/97	Bernstein et al.			
	A109	5,661.016	8/26/97	Lonberg et al.			
	A110	5,658.727	8/19/97	Barbas et al.			
	A111	5,648.239	7/15/97	Hawkins et al.			
	A112	5,633.425	5/27/97	Lonberg et al.			
	A113	5,625.126	4/29/97	Lonberg et al.			
	A114	5,622.929	4/22/97	Willner et al.			
	A115	5,618.709	4/8/97	Gewirtz et al.			
	A116	5,601.819	2/11/97	Wong et al.			
	A117	5,587.459	12/24/96	Uckun			
	A118	5,585.089	12/17/96	Queen et al.			
	A119	5,580.717	12/3/96	Dower et al.			
	A120	5,573.920	11/12/96	Randle			
	A121	5,571.698	11/5/96	Ladner et al.			
	A122	5,569.825	10/29/96	Lonberg et al.			
	A123	5,565.332	10/15/96	Hoogenboom et al.			
	A124	5,547.853	8/20/96	Wallner et al.			
	A125	5,545.806	8/13/96	Lonberg et al.			
	A126	5,530.101	6/25/96	Queen et al.			

	A127	5,516,637	5/14/96	Huang et al.			
	A128	5,447,851	9/5/95	Buetler et al.			
	A129	5,427,908	6/27/95	Dower et al.			
	A130	5,413,923	9/5/95	Kucherlapati et al.			
	A131	5,403,484	4/4/95	Ladner et al.			
	A132	5,359,046	10/25/94	Capon et al.			
	A133	5,349,053	9/20/94	Landolfi			
	A134	5,336,603	8/9/94	Capon et al.			
	A135	5,225,539	7/6/93	Winter			
	A136	5,223,409	6/29/93	Ladner et al.			
	A137	5,128,326	7/7/92	Balazs et al.			
	A138	5,122,464	6/16/92	Wilson et al.			
	A139	5,112,946	5/12/92	Maione			
	A140	4,980,286	12/25/90	Morgan et al.			
	A141	4,925,648	5/15/90	Hansen et al.			
	A142	4,816,567	3/28/89	Cabilly et al.			
	A143	4,816,397	3/28/89	Boss et al.			
	A144	4,741,900	5/3/88	Alvarez et al.			
	A145	4,716,111	12/29/87	Osband et al.			
	A146	4,714,681	12/22/87	Reading			
	A147	4,676,980	6/30/87	Segal et al.			
	A148	4,526,938	7/2/85	Churchill et al.			
	A149	4,474,893	10/2/84	Reading			
	A150	4,444,887	4/24/84	Hoffmann			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	EP 741 785	11/3/99	EPO				
	B02	EP 592 106	4/13/94	EPO				
	B03	EP 519 596	12/23/92	EPO				
	B04	EP 413 622	2/20/91	EPO				
	B05	EP 394 827	10/31/90	EPO				
	B06	EP 367 166	5/9/90	EPO				
	B07	EP 307 343	3/15/89	EPO				
	B08	EP 239 400	9/30/87	EPO				
	B09	WO 02/098370	12/12/02	PCT				
	B10	WO 02/069904	9/12/02	PCT				
	B11	WO 02/40049	5/23/02	PCT				
	B12	WO 01/77137	10/18/01	PCT				
	B13	WO 01/44301	6/21/01	PCT				
	B14	WO 00/78814	12/28/00	PCT				
	B15	WO 00/12113	3/9/00	PCT				
	B16	WO 99/23105	5/14/99	PCT				
	B17	WO 99/20253	4/29/99	PCT				
-	B18	WO 99/15154	4/1/99	PCT				

	B19	WO 99/04813	2/4/99	PCT				
	B20	WO 99/03502	1/28/99	PCT				
	B21	WO 98/50433	11/12/98	PCT				
	B22	WO 98/46645	10/22/98	PCT				
	B23	WO 98/33919	8/6/98	PCT				
	B24	WO 98/24893	6/11/98	PCT				
	B25	WO 98/23289	6/4/98	PCT				
	B26	WO 98/16654	4/23/98	PCT				
	B27	WO 98/07444	2/26/98	PCT				
	B28	WO 97/34911	9/25/97	PCT				
	B29	WO 97/34631	9/25/97	PCT				
	B30	WO 97/33899	9/18/97	PCT				
	B31	WO 97/13844	4/17/97	PCT				
	B32	WO 96/34096	10/31/96	PCT				
	B33	WO 96/33735	10/31/96	PCT				
	B34	WO 96/22024	7/25/96	PCT				
	B35	WO 96/20698	7/11/96	PCT				
	B36	WO 96/04388	2/15/96	PCT				
	B37	WO 95/20401	8/3/95	PCT				
	B38	WO 95/15982	6/15/95	PCT				
	B39	WO 94/25591	11/10/94	PCT				
	B40	WO 94/20619	9/15/94	PCT				
	B41	WO 94/12649	6/9/94	PCT				
	B42	WO 94/04678	3/3/94	PCT				
	B43	WO 93/20221	10/14/93	PCT				
	B44	WO 93/17715	9/16/93	PCT				
	B45	WO 93/17105	9/2/93	PCT				
	B46	WO 93/15200	8/5/93	PCT				
	B47	WO 93/15199	8/5/93	PCT				
	B48	WO 93/14188	7/22/93	PCT				
	B49	WO 93/11236	6/10/93	PCT				
	B50	WO 93/06866	4/15/93	PCT				
	B51	WO 93/06852	4/15/93	PCT				
	B52	WO 92/22635	12/23/92	PCT				
	B53	WO 92/22324	12/23/92	PCT				
	B54	WO 92/20316	11/26/92	PCT				
	B55	WO 92/18619	10/29/92	PCT				
	B56	WO 92/16622	10/1/92	PCT				
	B57	WO 92/08802	5/29/92	PCT				
	B58	WO 92/06180	4/16/92	PCT				
	B59	WO 92/05793	4/16/92	PCT				
	B60	WO 92/01047	1/23/92	PCT				
	B61	WO 91/10741	7/25/91	PCT				
	B62	WO 91/10737	7/25/91	PCT				
	B63	WO 91/09967	7/11/91	PCT				
	B64	WO 91/06570	5/16/91	PCT				

	B65	WO 91/05548	5/2/91	PCT				
	B66	WO 91/00360	1/10/91	PCT				
	B67	WO 90/02809	3/22/90	PCT				
	B68	WO 89/01036	2/9/89	PCT				
	B69	WO 88/07089	9/22/88	PCT				
	B70	WO 86/05807	10/9/86	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Abrams et al., 2000. "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells." J. Exp. Med. 192(5):681-694
	C02	Adkins et al., 2000. "A phase I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-CD2 monoclonal antibody, in the initial treatment of at least grade II acute graft-versus host disease." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00. Blood 96:476A Poster Board No. 784
	C03	Ames et al., 1995. "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins." J. Immunol. Methods 184:177-186
	C04	Anasetti et al., 2000. "Anti-CD3 F(AB') ₂ prevents Graft-Versus-Host Disease by selectively depleting donor T cells activated by recipient alloantigens." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
	C05	Arnon et al., 1985. "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," in: <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., eds., Alan R. Liss, Inc., pp. 243-256
	C06	Asadullah et al., 1999. "Interleukin-10 in Cutaneous Disorders: Implications for Its Pathophysiological Importance and Therapeutic Use." Arch. Dermatol. Res. 291(12):628-36
	C07	Ashcroft et al., 2000. "Therapeutic strategies for psoriasis." J. Clin. Pharm. Ther. 25(1):1-10
	C08	Ashkenazi et al., 1991. "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin." Proc. Natl. Acad. Sci. USA 88:10535-10539
	C09	Ausubel et al., eds., 1994, Current Protocols in Molecular Biology, John Wiley & Sons, NY, pp. 10.16.1 and 11.2.1
	C10	Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, NY, pp. 2.10.3 and 6.3.1 - 6.3.6
	C11	Baca et al., 1997. "Antibody humanization using monovalent phage display," J. Biol. Chem. 272(16):10678-10684
	C12	Bauer et al., 1999. "Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis." J. Pharmacokinet. Biopharm. 27(4):397-420
	C13	Bazarbachi & Hermine, 2002. "Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives." Virus Research 78(1-2):79-92
	C14	Berlin et al., 1992. "Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates." Transplantation 53(4):840-849
	C15	Besse et al., 1997. "Prevention of Rejection with BTI-322 After Renal Transplantation (Results at 9 Months)" Transplantation Proc. 29:2425-2426
	C16	Better et al., 1988. "Escherichia coli secretion of an active chimeric antibody fragment." Science 240(4855):1041-1043
	C17	Boesen et al., 1994. "Circumvention of chemotherapy-induced myelosuppression by transfer of the mdrl gene." Biotherapy 6(4):291-302
	C18	Bout et al., 1994. "Lung gene therapy: in vivo adenovirus-mediated gene transfer to rhesus monkey airway epithelium." Hum. Gene Ther. 5(1):3-10
	C19	Branco et al., 1999. "Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells." Transplantation 68(10):1588-1596
	C20	Brinkmann et al., 1995. "Phage display of disulfide-stabilized Fv fragments," J. Immunol. Methods 182(1):41-50
	C21	Buchwald et al., 1980. "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis." Surgery 88(4):507-516
	C22	Burton and Barbas, 1994. "Human antibodies from combinatorial libraries," Adv. Immunol. 57:191-280
	C23	Caldas et al., 2000. "Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen." Protein Eng. 13(5):353-360
	C24	Camisa, 2000. "Psoriasis: A Clinical Update on Diagnosis and New Therapies." Cleve. Clin. J. Med. 67(2):105-106
	C25	Carpenter et al., 2000. "Humanized non-FCR-binding anti-CD3 antibody as therapy for glucocorticoid refractory acute GVHD." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00. Location 305
	C26	Cathcart et al., 1986. "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen." Lab. Invest. 54:26-31
	C27	Chiorazzi, 1986. "Human monoclonal antibodies as probes to study autoimmune and allergic disorders." Biotechnology 4:210-218

C28	Chisholm et al., 1994, "The effects of an immunomodulatory LFA3-IgG ₁ fusion protein on nonhuman primates," <i>Therapeutic Immunity</i> 1:205-216
C29	Chong, 1996, "Receptors that turn on and turn off natural killer cells," <i>J Heart Lung Transplant</i> 15(7):675-683
C30	Chothia et al., 1998, "Structural determinants in the sequences of immunoglobulin variable domain," <i>J. Mol. Biol.</i> 278(2):457-479
C31	Cleek et al., 1997, "Biodegradable polymeric carriers for a bFGF antibody for cardiovascular application," <i>Pro. Intl. Symp. Control. Rel. Bioact. Mater.</i> 24:853-854
C32	Cline et al., 1985, "Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors," <i>Pharmacol. Ther.</i> 29(1):69-92
C33	Cockett et al., 1990, "High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification," <i>Biotechnology</i> 8(7):662-667
C34	Cohn et al., 1997, "Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production," <i>J. Exp. Med.</i> 186:1737-1747
C35	Cotten et al., 1993, "Receptor-mediated transport of DNA into eukaryotic cells," <i>Methods Enzymol.</i> 217:618-644
C36	Couriel et al., 2000, "Infliximab for the treatment of Graft-Versus-Host disease in allogeneic transplant recipients: an update," <i>Itinerary for the American Society of Hematology 42nd Annual Meeting</i> , 12/4/00, Poster Board Number 775
C37	Courtenay et al., 1980, "Immunisation against heterologous type II collagen induces arthritis in mice," <i>Nature</i> 283:666-668
C38	Couto et al., 1995, "Designing human consensus antibodies with minimal positional templates," <i>Cancer Res.</i> 55(23 Suppl):5973s-5977s
C39	Couto et al., 1995, "Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization," <i>Cancer Res.</i> 55(8):1717-1722
C40	Crofford and Wilder, 1993, "Arthritis and autoimmunity in animals," in: <i>Arthritis and Allied Conditions: A Textbook of Rheumatology</i> , McCarty et al., eds., Lee & Febiger, Chapter 29
C41	Cull et al., 1992, "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," <i>Proc. Natl. Acad. Sci. USA</i> 89(5):1865-1869
C42	Cwirla et al., 1990, "Peptides on phage: a vast library of peptides for identifying ligands," <i>Proc. Natl. Acad. Sci. USA</i> 87(16):6378-6382
C43	Davis et al., 1996, "The Structure and Ligand Interactions of CD2: Implications for T-Cell Function," <i>Immunology Today</i> 17(4):177-187
C44	Dearden et al., 2002, "Alemtuzumab in T-cell malignancies," <i>Med. Oncol.</i> 19 Suppl:S27-32
C45	Dearden et al., 2001, "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H," <i>Blood</i> 98(6):1721-1726
C46	Dehoux et al., 2000, "Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody," <i>Transplantation</i> 69:2622-2633
C47	De La Parra, et al., 1991, "Inhibition of T-Cell Activation by Lo-CD2-a, A Rat monoclonal Antibody Against the Human CD2 Glycoprotein," <i>Belgian Journal of Zoology</i> 121(Suppl.1):13 Abstract 16
C48	Denardo et al., 1998, "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N''-N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts," <i>Clin. Cancer Res.</i> 4(10):2483-2490
C49	Denning et al., 1987, "Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation," <i>J. Immunol.</i> 139(8):2573-2578
C50	Devlin, 1990, "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> 249(4967):404-406
C51	Diasio et al., 1996, "Immunomodulators: Immunosuppressive agents and immunostimulants," in: <i>The Pharmacological Basis of Therapeutics</i> , McGraw-Hill, New York, Ch. 52, pp. 1291-1306
C52	DiSepio et al., 2000, "New Drugs in the Treatment of Psoriasis," <i>Expert Opin. Investig. Drugs</i> 9(1):79-93
C53	Dumont et al., 1998, "Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T Cells," <i>J. Immunol.</i> 3797-3804
C54	During et al., 1989, "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," <i>Ann. Neurol.</i> 25:351-356
C55	Ellis, 1999, "Quality of Life (QOL) of Amevive TM (LFA3TIP) in patients with chronic plaque psoriasis," <i>Amevive Breakfast Meeting</i> , 12/3/99 and abstract from <i>Br. J. Dermatol.</i> 141:990 Abstract 82
C56	Ellis et al., "Quality of Life (QOL) in Patients with Chronic Psoriasis Treated with AMEVIVE (LFA3TIP)," <i>Poster Presentation</i>
C57	Feldmann, M., 1999, "Cytokine Inhibitors: Biologics," In: <i>Inflammation: Basic Principles and Clinical Correlates</i> 3 rd Edition, Ed. Gillian and Synderman, Lippincott Williams & Wilkins (Philadelphia) pp. 1207-1212
C58	Felici, 1991, "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector," <i>J. Mol. Biol.</i> 222(2):301-310
C59	Ferrant et al., 1997, "LO-CD2a/BTI322 for Steroid Resistant Graft-Versus-Host Disease," <i>BTI Ref</i> 1979, <i>Transplant</i> 19(Suppl. 1): S181 Abstract P721
C60	Flanders et al., 1999, "Prevention of type 1 diabetes from laboratory to public health," <i>Autoimmun.</i> 29:235-246
C61	Fodor, 1993, "Multiplexed biochemical assays with biological chips," <i>Nature</i> 364(6437):555-556
C62	Foecking and Hofstetter, 1986, "Powerful and versatile enhancer-promoter unit for mammalian expression vectors,"

		Gene 45:101-105
	C63	Foster. 1999. "Relevance of systemic lupus erythematosus nephritis animal models to human disease." Semin. Nephrol. 19(1):12-24
	C64	Fredriksson and Pettersson. 1978. "Severe psoriasis--oral therapy with a new retinoid." Dermatologica 157(4):238-244
	C65	Fujiwara et al.. 2002. "Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma." Acta. Haematol. 107(4):213-219
	C66	GenBank Accession No. X06143
	C67	GenBank Accession No. E12817
	C68	GenBank Accession No. CAA29622
	C69	GenBank Accession No. AH002740
	C70	GenBank Accession No. M16445
	C71	Gentz et al.. 1989. "Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis." Proc. Natl. Acad. Sci. USA 86(3):821-824
	C72	Gillies et al.. 1989. "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes." J. Immunol. Methods 125:191-202
	C73	Goldspiel et al.. 1993. "Human gene therapy." Clin. Pharm. 12(7):488-505
	C74	Goodson. 1984. "Dental Applications." in: <u>Medical Applications of Controlled Release</u> , Langer and Wise, eds., vol. 2. Ch. 6. pp. 115-138
	C75	Gottlieb et al.. 2000. "Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study." J. Am. Acad. Dermatol. 43(4):595-604
	C76	Gottlieb et al.. 2000. "Effects of administration of a single does of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis." J. Am. Acad. Dermatol. 42(3):428-435
	C77	Greaves and Weinstein. 1995. "Treatment of psoriasis." N. Eng. J. Med. 332(9):581-588
	C78	Greenspan & Bona. 1993. "Idiotypes: structure and immunogenicity." FASEB J. 7(5):437-444
	C79	Griffiths. 1999. "T cell targeting for psoriasis." Amevive Breakfast Meeting, 12/3/99
	C80	Guzzo et al.. 1996. "Dermatological pharmacology," in: <u>The Pharmacological Basis of Therapeutics</u> , McGraw-Hill, New York, Ch. 64. pp. 1593-1613
	C81	Hammerling et al.. 1981. in: <u>Monoclonal Antibodies and T-Cell Hybridomas</u> , pp. 563-587
	C82	Hansra et al.. 2000. "Carrageenan-induced arthritis in the rat." Inflammation 24:141-155
	C83	Hatta et al.. 2002. "Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)." Leukemia 16(6):1069-1085
	C84	Hellstrom et al.. 1987. "Antibodies for drug delivery." in: <u>Controlled Drug Delivery 2nd</u> ed., Robinson et al., eds., Marcel Dekker, Inc. pp. 623-653
	C85	Heslop et al.. 2000. "ABX-CBL monoclonal antibody in patients with steroid resistant graft versus host disease." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00. Abstract 305
	C86	Holmdahl. 1999. "Autoimmunity: Another pathway towards arthritis." Curr. Biol. 9:R528-530
	C87	Houghten. 1992. "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides." Biotechniques 13(3):412-421
	C88	Howard et al.. 1989. "Intracerebral drug delivery in rats with lesion-induced memory deficits." J. Neurosurg. 71(1):105-112
	C89	Husted et al.. 1995. "A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis." Clin. Exp. Rheumatol. 13(4):439-443
	C90	Inouye and Inouye. 1985. "Up-promoter mutations in the lpp gene of Escherichia coli." Nucl. Acids Res. 13(9):3101-3110
	C91	Jemec and Wulf. 1997. "The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis." Acta Derm. Venereol. 77(5):392-393
	C92	Joliot et al.. 1991. "Antennapedia homeobox peptide regulates neural morphogenesis." Proc. Natl. Acad. Sci. USA 88:1864-1868
	C93	Kantarjian et al.. 2002. "Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate." Clin. Cancer Res. 8(7):2167-2176
	C94	Kaplon et al.. 1996. "Short Course Single Agent Therapy with an LFA-3-IgG1 Fusion Protein Prolongs Primate Cardiac Allograft Survival." Transplantation 61(3):356-363
	C95	Kettleborough et al.. 1994. "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments." Eur. J. Immunol. 24(4):952-958
	C96	Kim and Berstad. 1992. "Experimental colitis in animal models." Scand. J. Gastroenterol. 27(7):529-537
	C97	Koller and Smithies. 1989. "Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination." Proc. Natl. Acad. Sci. USA 86(22):8932-8935
	C98	Kostelny et al.. 1992. "Formation of a bispecific antibody by the use of leucine zippers." J. Immunol. 148(5):1547-

	1553
C99	Kozarsky et al., 1993, "An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites." <i>Cell Immunol.</i> 150(2):235-246
C100	Kozarsky et al., 1993, "Gene therapy: adenovirus vectors." <i>Curr. Opin. in Genetics and Devel.</i> 3(3):499-503
C101	Krieger et al., 1997, "The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection." <i>J. Heart Lung Transplant.</i> 16:263-267
C102	Krogh et al., 1999, "Models to study the pathogenesis of thyroid autoimmunity." <i>Biochimie</i> 81(5):511-515
C103	Krueger et al., 2000, "Anti-CD11a Treatment for Psoriasis Concurrently Increases Circulating T-cells and Decreases Plaque T-cells. Consistent with Inhibition of Cutaneous T-cell Trafficking." <i>J. Invest. Dermatol.</i> 115(2):333
C104	Krueger et al., 2000, "Successful in vivo Blockade of CD25 (High-Affinity Interleukin 2 Receptor) on T Cells by Administration of Humanized Anti-Tac Antibody to Patients with Psoriasis." <i>J. Am. Acad. Dermatol.</i> 43(3):448-458
C105	Krueger, 1999, "Efficacy and safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis." Amevive Breakfast Meeting 12/3/99
C106	Krueger, 1999, "Phase II trial results of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis." <i>Br. J. Dermatol.</i> 141:979-980. Abstract 39
C107	Kutemeier et al., 1994, "Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR." <i>Biotechniques</i> 17(2):242-246
C108	Lafaille et al., 1994, "High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice." <i>Cell</i> 78(3):399-408
C109	Lam et al., 1997, "Microencapsulation of recombinant humanized monoclonal antibody for local delivery," <i>Proc. Intl. Symp. Control. Rel. Bioact. Mater.</i> 24:759-760
C110	Lam, 1991, "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> 354(6348):82-84
C111	Langer, 1990, "New methods of drug delivery." <i>Science</i> 249(4976):1527-1533
C112	Langer and Peppas, 1983, "Chemical and physical structure of polymers as carriers for controlled release of bioreactive agents: a review." <i>J. Macromol. Sci. Rev. Macromol. Chem. and Physics</i> C23(1):61-126
C113	Latinne et al., 1997, "BTI-322, An Anti-Human CD2 MAB. Elicits Specific Depletion of T Cells Activated by Anti-TCR VbMAB." Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
C114	Latinne et al., 1996, "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro." <i>Int. Immunol.</i> 8(7):1113-1119
C115	Lebwohl, 2000, "Advances in psoriasis therapy." <i>Dermatol. Clin.</i> 18(1):13-19
C116	Lerut et al., "The Use of Tacrolimus (TAC) and Anti-CD2 Antibody Lo-CD2a (BTI-322) in Adult Liver Transplantation (LT): Preliminary Results of a Prospective Randomized Study." Abstract 102
C117	Levy et al., 1985, "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate." <i>Science</i> 228(4696):190-192
C118	Li et al., 1995, "CD2 Antigen: Signaling Features and Strategies to Inhibit CD2 Antigen-Derived Signals." in <i>Recent Developments in Transplantation Medicine V.2. Ch. 7.</i> Salomon and Sollinger, eds., pp. 97-121
C119	Linden et al., 1999, "Psoriasis: Current Perspectives with an Emphasis on Treatment." <i>Am. J. Med.</i> 107(6):595-605
C120	Loeffler and Behr, 1993, "Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA." <i>Methods Enzymol.</i> 217:599-618
C121	Lonberg and Huzar, 1995, "Human antibodies from transgenic mice." <i>Int. Rev. Immunol.</i> 13(1):65-93
C122	Lopez-Berestein et al., 1989, "Treatment of systemic fungal infections with liposomal amphotericin B," in: <i>Liposomes in the Therapy of Infectious Disease and Cancer.</i> Lopez-Berestein and Fiedler, eds., Alan R. Liss, NY, pp. 317-327
C123	Magilavy et al., "Immunopharmacologic effects of AMEVIVE™ (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45RO+) over naïve (CD45RA+) T cells." Poster presentation and abstract from <i>Br. J. Dermatol.</i> 141:990. Abstract 81
C124	Magilavy et al., 2000, "The Response of Plaque Psoriasis to Amevive™ (LFA3TIP) and the Selective Suppression of Memory/Effector T Cells (CD45RO+) Verses Naïve T Cells (CD45RA+) Is Serum Levels of LFA3TIP." <i>J. Invest. Dermatol.</i> 114(4):776 Abstract 148
C125	Magilavy et al., 1999, "Pharmacodynamic effects of Amevive™ (LFA3TIP), a LFA-3/igg Fc fusion protein in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naïve (CD45RA+) T cells." Amevive Breakfast Meeting, 12/3/99
C126	Majeau et al., 1994, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses." <i>J. Immunol.</i> 152(6):2753-2767
C127	Margolis et al., 2000, "Pentostatin: A novel treatment for steroid refractory acute GHVD." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00. Poster Board Number 774
C128	Mastrangeli et al., 1993, "Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer." <i>J. Clin. Invest.</i> 91(1):225-234
C129	Matutes et al., 1991, "Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia." <i>Blood</i> 78(12):3269-7324
C130	Meier et al., 1995, "Immunomodulation by LFA3TIP, an LFA-3/IgG1 Fusion Protein: Cell Line Dependent Glycosylation Effects on Pharmacokinetics and Pharmacodynamic Markers." <i>Ther. Immunol.</i> 2(3):159-171

C131	Merck Manual of Diagnosis and Therapy, Seventeenth Edition. Ed. Beers and Berkow. Merck Research Laboratories (Whitehouse Station, NJ), 1999. pages 416-423
C132	Miller et al., 1993, "Use of retroviral vectors for gene transfer and expression." <i>Methods Enzymol.</i> 217:581-599
C133	Miller et al., 1993, "Specific Interaction of Lymphocyte Function-Associated Antigen 3 with CD2 Can Inhibit T Cell Responses." <i>J. Exp. Med.</i> 178:211-222
C134	Mohammad et al., 1999, "A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model." <i>Int. J. Oncol.</i> 15(2):367-372
C135	Mollee et al., 2000, "Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GHVD." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00
C136	Mollereau et al., 1999, "Effects of Anti-CD2 Monoclonal Antibody: CD2- and CD95-Mediated Apoptosis of Human Peripheral T Cells." <i>Transplantation Proc.</i> 31:1245
C137	Morea et al., 2000, "Antibody modeling: implications for engineering and design." <i>Methods</i> 20(3):267-279
C138	Morgan and Anderson, 1993, "Human gene therapy." <i>Ann. Rev. Biochem.</i> 62:191-217
C139	Morrison et al., 1986, "Chimeric Antibodies." <i>BioTechniques</i> 4(3):214
C140	Morrison, 1985, "Transfectomas provide novel chimeric antibodies." <i>Science</i> 229(4719):1202-1207
C141	Mourad et al., 1997, "BTI-322 for Acute Rejection After Renal Transplantation." <i>Transplantation Proc.</i> 29:2353
C142	Mulligan, 1993, "The basic science of gene therapy." <i>Science</i> 260(5110):926-932
C143	Mullinax et al., 1992, "Expression of a heterodimeric Fab antibody protein in one cloning step." <i>BioTechniques</i> 12(6):864-869
C144	Muyldermans, 2001, "Single domain camel antibodies: current status." <i>J. Biotechnol.</i> 74(4):277-302
C145	Nabel et al., 1993, "Direct gene transfer for immunotherapy and immunization." <i>TIBTECH</i> 11(5):211-215
C146	Ning et al., 1996, "Intratumoral radioimmunotherapy of human colon cancer xenograft using a sustained-release gel." <i>Radiotherapy & Oncology</i> 39:179-189
C147	Nisonoff, 1991, "Idiotypes: concepts and applications." <i>J. Immunol.</i> 147(8):2429-2438
C148	Nizet et al., 2000, "The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322." <i>Transplantation</i> 69(7):1420-1428
C149	Nuttall et al., 2000, "Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents." <i>Curr. Pharm. Biotechnol.</i> 1(3):253-263
C150	Ohno et al., 2002, "Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I." <i>Leuk. Lymphoma</i> 43(4):885-888
C151	Order et al., eds., 1985, "Analysis, results, and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Academic Press, Baldwin et al., eds., Ch. 15 pp. 303-316
C152	Ortonne, 1999, "Recent Developments in the Understanding of the Pathogenesis of Psoriasis." <i>Br. J. Dermatol.</i> 140 Suppl 54:1-7
C153	Padlan, 1991, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties." <i>Mol. Immunol.</i> 28(4-5):489-498
C154	Papp et al., 1999, "The treatment of moderate to severe psoriasis with hu1124: a new monoclonal antibody." <i>Br. J. Dermatol.</i> 141:980, Abstract 40
C155	Pasquini et al., 2000, "Basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist - as therapy for refractory acute Graft Versus Host Disease (a-GHVD) following bone marrow transplantation (BMT)." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board No. 762
C156	Paul, ed., 1989, <i>Fundamental Immunology</i> 2 nd Ed., Raven Press, NY, pp. 332-336
C157	Pedersen et al., 1994, "Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies." <i>J. Mol. Biol.</i> 235(3):959-973
C158	Peipp et al., 2002, "A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells." <i>Cancer Res.</i> 62(10):2848-2855
C159	Persic et al., 1997, "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries." <i>Gene</i> 187(1):9-18
C160	Peters et al., 2000, "Pathophysiology and treatment of psoriasis." <i>Am. J. Health Sys. Pharm.</i> 57(7):645-659
C161	Peterson et al., 1999, "Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates." <i>Bioconjug. Chem.</i> 10(4):553-557
C162	Peterson et al., 1987, "Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2)." <i>Nature</i> 329(6142):842-846
C163	Phillips et al., 2000, "IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction." <i>Cancer Res.</i> 60(24):6977-6984
C164	Potter et al., 2000, "Campath 1 H 'In the Bag' is an effective method of GHVD prevention in allogeneic stem cell transplantation." Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305
C165	Przepiorika et al., "Pharmacokinetics and Safety of BTI-322, a Rat Anti-CD2 Monoclonal Antibody for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease." BTI Ref 3623

C166	Przepiorka et al., 1998, "A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease." <i>Blood</i> 92(11):4066-4071
C167	Rabinowitz et al., 1995, "In vitro activation leads to the binding of T-cell markers to the surface of B-lymphocytes." <i>Clin. Immunol. Immunopathol.</i> 76(2):148-154
C168	Ratanathathorn et al., 1999, "Pharmacokinetics and Safety of Medi-507, a Humanized Anti-CD2 Monoclonal Antibody in Severe Steroid-Resistant Graft-Versus-Host Disease." <i>International Society for Experimental Hematology, Abstract</i> 119
C169	Riechmann et al., 1999, "Single domain antibodies: comparison of camel VH and camelised human VH domains." <i>J. Immunol. Methods</i> 231(1-2):25-38
C170	Riechmann et al., 1988, "Reshaping human antibodies for therapy," <i>Nature</i> 332(6162):323-327
C171	Riddell et al., 2002, "T-cell therapy of leukemia." <i>Cancer Control</i> 9(2):114-122
C172	Robert et al., 1999, "Inflammatory skin diseases. T cells, and immune surveillance." <i>New England J of Med.</i> 341(24):1817-1828
C173	Robinson et al., eds., 1987, Marcel Dekker, Inc. pp. 623-653
C174	Roenigk et al., 1988, "Methotrexate in psoriasis: revised guidelines." <i>J. Am. Acad. Dermatol.</i> 19(1 pt. 1):145-156
C175	Roguska et al., 1996, "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing." <i>Protein Eng.</i> 9(10):895-904
C176	Roguska et al., 1994, "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci. USA</i> 91:969-973
C177	Rosenfeld et al., 1992, "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium." <i>Cell</i> 68(1):143-155
C178	Rosenfeld et al., 1991, "Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo." <i>Science</i> 252(5004):431-434
C179	Rouleau et al., 1997, "CD2 Induced Apoptosis of Peripheral T Cells." <i>Transplantation Proc.</i> 29:2377-2378
C180	Ruther and Muller-Hill, 1983, "Easy identification of cDNA clones," <i>EMBO J.</i> 2(10):1791-1794
C181	Sandhu, 1994, "A rapid procedure for the humanization of monoclonal antibodies." <i>Gene</i> 150(2):409-410
C182	Saudek et al., 1989, "A preliminary trial of the programmable implantable medication system for insulin delivery." <i>N. Engl. J. Med.</i> 321(9):574-579
C183	Sawai et al., 1995, "Direct production of the Fab fragment derived from the sperm immobilizing antibody using polymerase chain reaction and cDNA expression vectors." <i>Am. J. Reprod. Immunol.</i> 34(1):26-34
C184	Schad et al., 1996, "An Anti-CD2 Monoclonal Antibody That Elicits Alloantigen-Specific Hyporesponsiveness." <i>Transplantation Proceedings</i> 28(4):2051-2053
C185	Scott and Smith, 1990, "Searching for peptide ligands with an epitope library." <i>Science</i> 249(4967):386-390
C186	Sefton, 1987, "Implantable pumps." <i>Crit. Rev. Biomed. Eng.</i> 14(3):201-240
C187	Siegel et al., 2001, "Human T-cell lymphotropic-I-associated leukemia/lymphoma." <i>Curr. Treat. Options Oncol.</i> 2(4):291-300
C188	Song et al., 1995, "Antibody mediated lung targeting of long circulating emulsions." <i>PDA J. Pharm. Science & Tech.</i> 50:372-397
C189	Spitzer et al., 2000, "Haploidentical donor bone marrow transplantation for advanced hematologic malignancy following non-myeloablative preparative therapy: role of in vivo T cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy." <i>Blood</i> 96:841A
C190	Squifflet et al., 1997, "BTI-322 for Induction Therapy After Renal Transplantation: A Randomized Study." <i>Transplant Proc.</i> 29(1-2):317-319
C191	Squifflet et al., 1997, "A Randomized Study of BTI-322 for the Prevention of Renal Allograft Rejection: One Year Follow Up." Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14
C192	Stern and Laird, 1994, "The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study." <i>Cancer</i> 73(11):2759-2764
C193	Stockdale, 1998, "Principles of cancer patient management." in <i>Scientific American: Medicine</i> , vol. 3, Rubenstein Federman, Ch. 12, Section IV
C194	Strober, 1985, "Animal models of inflammatory bowel disease - an overview," <i>Dig. Dis. Sci.</i> 30(12 suppl.):3S-10S
C195	Studnicka et al., 1994, "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues." <i>Protein Eng.</i> 7(6):805-814
C196	Sultan et al., 1997, "Blockade of CD2-LFA-3 Interactions Protects Human Skin ALlografts in Immunodeficient Mouse/Human Chimeras." <i>Nature Biotechnology</i> 15:759-762
C197	Takahashi et al., 1994, "Human Fas ligand: gene structure, chromosomal location and species specificity." <i>Int. Immunol.</i> 6(10):1567-1574
C198	Takemori et al., 1995, "Significance of PUVA therapy for adult T-cell leukemia/lymphoma - PUVA therapy can induce apoptosis in leukemic cells." <i>Hum. Cell.</i> 8(3):121-126
C199	Tan et al., 2002, "Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia." <i>Cancer Res.</i> 62(4):1083-1086

C200	Tan et al., 2002, "'Superhumanized' antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28." J. Immunol. 169(2):1119-1125
C201	Thorpe, 1985, "Antibody carriers of cytotoxic agents in cancer therapy: a review," in: <u>Monoclonal Antibodies '84: Biological and Clinical Applications</u> , Pinchera et al., eds., pp. 475-506
C202	Thorpe and Ross, 1982, "The preparation and cytotoxic properties of antibody-toxin conjugates." Immunol. Rev. 62:119-158
C203	Tolstoshev, 1993, "Gene therapy, concepts, current trials and future directions." Ann. Rev. Pharmacol. Toxicol. 32:573-596
C204	Traunecker et al., 1988, "Soluble CD4 molecules neutralize human immunodeficiency virus type 1." Nature 331(6151):84-86
C205	Treat et al., 1989, in <i>Liposomes in the Therapy of Infectious Disease and Cancer</i> , Lopez-Berestein and Fidler, eds., Liss, New York, pp. 353-365
C206	Trentham et al., 1977, "Autoimmunity to type II collagen an experimental model of arthritis." J. Exp. Med. 146(3):857-868
C207	Tutt et al., 1991, "Trispecific F(ab') ₃ derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells." J. Immunol. 147(1):60-69
C208	Van Heeke and Schuster, 1989, "Expression of human asparagine synthetase in Escherichia coli." J. Biol. Chem. 264(10):5503-5509
C209	Vie et al., 1992, "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor." Proc. Natl. Acad. Sci. USA 89:11337-11347
C210	Walsh et al., 1993, "Gene therapy for human hemoglobinopathies." Proc. Soc. Exp. Biol. Med. 204(3):289-300
C211	Wang et al., 1995, "A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions." Gene Ther. 2(10):775-783
C212	Wilson et al., 1984, "The structure of an antigenic determinant in a protein." Cell 37(3):767-778
C213	Winter et al., 1962, "Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs." Proc. Soc. Exp. Biol. Med. 111:544-547
C214	Woodward et al., 1996, "Blockade of multiple costimulatory receptors induces hyporesponsiveness." Transplantation 62(7):1011-1018
C215	Woyke et al., 2002, "Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans." Antimicrob. Agents. Chemother. 46(12):3802-3808
C216	Woyke et al., 2001, "In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE." Antimicrob. Agents Chemother. 45(12):3580-3584
C217	Wu et al., 1991, "Delivery systems for gene therapy." Biotherapy 3(1):87-95
C218	Wu et al., 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system." J. Biol. Chem. 262(10):4429-4432
C219	Xu et al., 2000, "Inhibition of human anti-pig T cell response by anti-CD2, anti-CD40L, and CTLA4-Ig: a comparative study." Transplant. Proc. 32(5):926
C220	Yamada, 1983, "Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma." Blood 61(1):192-199
C221	Yamamoto et al., 1998, "The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats." Endocrinol. 139(3):1411-1419
C222	Yoshitake et al., 1999, "Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption." Proc. Natl. Acad. Sci. USA 96:8156-8160
C223	Zamvil and Steinman, 1990, "The T lymphocyte in experimental allergic encephalomyelitis." Annu. Rev. Immunol. 8:579-621
C224	Zheng et al., 1995, "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation." J. Immunol. 154(10):5590-5600
C225	Zijlstra et al., 1989, "Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells." Nature 342(6248):435-438
C226	Zimmermann et al., 1999, "A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab') ₂ fragments." Nucl. Med. Biol. 26(8):943-950

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.